Thursday, 02 April 2020

Drug Discovery News

  • MerLion completes phase I of finafloxacin study

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 08 Nov, 2012

    Singapore: Following successful first-in-man phase I and two phase IIa clinical studies with the oral formulation of finafloxacin, Singapore-based MerLion Pharmaceuticals has completed firs...Read more

  • Changing the paradigm of drug development

    Drug Discovery |  Opinion | By BioSpectrum Bureau  | 0 Comment | 08 Feb, 2013

    Recent promising data on drug approvals in 2011 shows that there were 35 new molecular entities (NME) approved by the FDA. This is the largest haul of any year over the last decade with the...Read more

  • Medivir, Daewoong end hepatitis drug development

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 09 Sep, 2013

    Singapore: Sweden-based Medivir has discontinued the development of its hepatitis B compound MIV-210 based on a joint decision with Korea-based Daewoong Pharmaceutical. Under the terms of t...Read more

  • Eisai reveals phase III results of breast cancer drug Halaven

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 10 Jul, 2012

    Singapore: Eisai revealed its preliminary results from a recently completed phase III study of Halaven versus capecitabine (Xeloda) in women with locally advanced or metastatic breast cance...Read more

  • Antidepressant can treat sickle cell disease

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 20 Feb, 2013

    Singapore: A study by researchers at the University of Michigan Medical School, US, found that antidepressant drug tranylcypromine (TCP) can reverse the effects of sickle cell disease in m...Read more

  • Pharmaxis to launch cystic fibrosis drug in Europe

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 11 Jun, 2012

    Singapore: Australian pharmaceutical company Pharmaxis is all set to launch Bronchitol for cystic fibrosis (CF) patients in the UK and Germany, following the approval by the European Medici...Read more

  • UK firm withdraws insulin marketing applications

    Drug Discovery |  Regulatory | By BioSpectrum Bureau  | 0 Comment | 28 Nov, 2012

    Singapore: UK's Marvel LifeScience, insulin marketing company, has withdrawn its application for centralized marketing authorizations for the medicines Solumarv, Isomarv and Combimarv (huma...Read more

  • Alchemia enrolls patients for cancer trial

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 01 Mar, 2013

    Singapore: Alchemia has completed enrollment of patients in a pivotal phase III clinical trial evaluating its lead product, HA-Irinotecan, for the treatment of metastatic colorectal cancer...Read more

  • Bayer, 5 cancer institutes set up oncology network

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 10 Jan, 2013

    Sinapore: Bayer HealthCare in Singapore in collaboration with five research institutions have kaunched new Integrated Translational Oncology Network to enhance R&D collaborations in fig...Read more

  • Daiichi develops antibody to prevent fracture

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 16 Oct, 2012

    Singapore: Daiichi Sankyo's 24-month randomized, double-blind, placebo-controlled multi-center phase III clinical trial with AMG 162 (denosumab) (Denosumab fracture Intervention Randomized ...Read more

  • Gilead to halt phase III study of leukemia drug

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 10 Oct, 2013

    Singapore: Gilead Sciences plans to halt phase III study evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy. Idelalisi...Read more

  • Sihuan, NeuroVive to develop heart and brain products

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 21 Nov, 2012

    Singapore: Sihuan Pharmaceutical entered into a collaboration agreement with NeuroVive Pharmaceutical to develop two innovative products, CicloMulsion and NeuroSTAT, which are used for the...Read more

  • Bioxyne to report COPD trial results in June

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 29 May, 2012

    Singapore: Australian company Bioxyne closed its 320-patient study, which was designed to evaluate the efficacy and safety of the Bioxyne's HI-164OV therapy for patients with chronic obstru...Read more

  • MicuRx next gen antibiotic gets US patent

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 24 May, 2012

    Singapore: MicuRx Pharmaceuticals, a privately-held biopharmaceutical company developing next-generation antibiotics, has received a composition of matter patent covering its clinical candi...Read more

  • MedImmune, UCSF enter 3-year R&D deal

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 18 Feb, 2014

    Singapore: MedImmune, the global biologics R&D arm of AstraZeneca, has entered into a three-year collaboration with the Clinical and Translational Science Institute (CTSI) at the Univer...Read more

  • Biogen to commercialize MS therapies in Asia

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 11 Feb, 2014

    Singapore: Belgium based pharmaceutical company UCB and global pharmaceutical company, Biogen, have entered into an agreement where UCB gets the right to commercialize Biogen's multiple scl...Read more

  • BD launches Cell Analyzer to enhance drug discovery

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 11 Jul, 2013

    Singapore: BD Biosciences, a global medical technology company, has launched BD LSRFortessa X-20 Cell Analyzer, to deliver high-performance multicolor analysis with compact footprint in its...Read more

  • Viralytics melanoma study shows +ve results

    Drug Discovery |  News | By BioSpectrum Bureau  | 0 Comment | 25 Mar, 2013

    Singapore: Assistant Professor (Dr) Robert H I Andtbacka presented a summary of his ongoing study with Viralytics' Cavatak clinical trial at the HemOnc Today Melanoma and Cutaneous Malignan...Read more